Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 551-560 of 969 for hematology

Edit search filters
  1. Low-Dose or High-Dose Lenalidomide in Treating Children with Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

    Rochester, MN

  2. SC16LD6.5 in Recurrent Small Cell Lung Cancer

    Rochester, MN

  3. Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. A Study to Evaluate Gilteritinib vs. Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

    Jacksonville, FL, Rochester, MN

  5. Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

    Rochester, MN

  6. Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

    Rochester, MN

  7. Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

    Jacksonville, FL, Rochester, MN

  8. Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma

    Rochester, MN

  9. Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

    Rochester, MN

  10. A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

    Rochester, MN

.

Mayo Clinic Footer